Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer

Prostate

Volumn 69, Issue 8, 2009, Pages 820-826

  Sung, Kyu Hong ^a   Seung, Tae Lee ^a   Sung, Soo Kim ^a   Kyung, Eun Min ^a   Byun, Seok Soo ^a   Sung, Yong Cho ^a   Choe, Gheeyoung ^a   Sang, Eun Lee ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Diabetes mellitus; HbA1c; Prostate cancer; Prostatectomy

Indexed keywords

HEMOGLOBIN A1C; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER LOCALIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; GLEASON SCORE; GLYCEMIC CONTROL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; BIOPSY; BLOOD; BODY MASS; CANCER STAGING; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PREOPERATIVE CARE; PROSTATE TUMOR; RETROSPECTIVE STUDY; SEMINAL VESICLE;

AGED; BIOLOGICAL MARKERS; BIOPSY; BODY MASS INDEX; DIABETES COMPLICATIONS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEMINAL VESICLES;

EID: 65549118658     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20932     Document Type: Article

References (29)

1. OMara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: A multisite case-control study. J Chronic Dis 1985;38:435-441.
2. Weiderpass E, Gridley G, Persson I, Nyrén O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 1997;71:360-363. (Pubitemid 27224297)
3. Larsson SC, Giovannucci E, Wolk A. Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care 2005;28:1805-1807. (Pubitemid 40923101)
4. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, Schwartz AG, Brown LM, Greenberg RS, Schoenberg JB, Pottern LM, Hoover RN, Fraumeni JF Jr., Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999;80:1830-1837. (Pubitemid 29389642)
5. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study. Gut 2005;54:533-539.
6. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998;9:3-9. (Pubitemid 28048654)
7. Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004;159:978-982. (Pubitemid 38608275)
8. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005;161:147-152. (Pubitemid 40096789)
9. Rosenberg DJ, Neugut AI, Ahsan H, Shea S. Diabetes mellitus and the risk of prostate cancer. Cancer Invest 2002;20:157-165. (Pubitemid 34205481)
10. Calton BA, Chang SC, Wright ME, Kipnis V, Lawson K, Thompson FE, Subar AF, Mouw T, Campbell DS, Hurwitz P, Hollenbeck A, Schatzkin A, Leitzmann MF. History of diabetes mellitus and subsequent prostate cancer risk in the NIHAARP Diet and Health Study. Cancer Causes Control 2007;18:493-503. (Pubitemid 46684823)
11. Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control 2005;16:789-797. (Pubitemid 41160043)
12. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163. (Pubitemid 38068335)
13. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, Persson I. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-314.
14. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-1167. (Pubitemid 38747263)
15. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002;102:258-261. (Pubitemid 35222294)
16. Gonzalez-Perez A, Garcia Rodriguez LA. Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 2005;16:1055-1058. (Pubitemid 41356002)
17. Coker AL, Sanderson M, Zheng W, Fadden MK. Diabetes mellitus and prostate cancer risk among older men: Population based case-control study. Br J Cancer 2004;90:2171-2175.
18. Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: Diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev 1995;14:807-811.
19. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case control study among men from Montreal, Canada. Int J Cancer 2006;118:2105-2109.
20. Batty GD, Shipley MJ, Marmot M, Smith GD. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: Findings from the original Whitehall study. Cancer Causes Control 2004;15:873-881.
21. Tavani A, Gallus S, Bertuzzi M, Dal Maso L, Zucchetto A, Negri E, Franceschi S, Ramazzotti V, Montella M, La Vecchia C. Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 2005;47:313-317. (Pubitemid 40248849)
22. Kasper JS, Giovannucci E. A Meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2056-2062.
23. Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, Huang WY, Weiss JM, Danforth KN, Grubb RL III, Andriole GL. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 2008;19:1267-1276.
24. Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A, Liu K. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 2001;12:763-772. (Pubitemid 32803503)
25. Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B. Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: A case-control study. Dig Dis Sci 2008;53:2486-2494.
26. Hammarsten J, Hogstedt B. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005;41:2887-2895.
27. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-819.
28. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003;35:694-704. (Pubitemid 38058173)
29. Krone KA, Ely JT. Controlling hyperglycemia as an adjunct to cancer therapy. Integr Cancer Ther 2005;4:25-31. (Pubitemid 40250675)